Candriam S.C.A. Krystal Biotech, Inc. Transaction History

Candriam S.C.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$96.0 - $128.29 $1.44 Million - $1.92 Million	-15,000 Reduced 21.43%	55,000 $6.82 Million
Q2 2023 Aug 08, 2023	SELL	$78.48 - $130.32 $1.73 Million - $2.87 Million	-22,000 Reduced 23.91%	70,000 $8.22 Million
Q1 2023 May 12, 2023	BUY	$72.39 - $84.27 $6.66 Million - $7.75 Million	92,000 New	92,000 $7.37 Million

298

24.3M

388K

233K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $4.52B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.